BGI Genomics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Lijian Zhao

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.9yrs
Participación del CEO	0.02%
Permanencia media de la dirección	8.9yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Apr 21

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Mar 25

CEO

Lijian Zhao (47 yo)

2.9yrs

Permanencia

Mr. Lijian Zhao serves as a Director of BGI Genomics Co., Ltd., since June 17, 2021 and serves its General Manager.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ye Yin	Vice Chairman of the Board	8.9yrs	CN¥2.62m	0.28% CN¥ 44.5m
Yutao Du	COO, Deputy GM & Director	less than a year	CN¥453.10k	0.025% CN¥ 3.9m
Qian Xu	Director of Legal Affairs	8.9yrs	CN¥870.90k	0.0021% CN¥ 334.7k
Na Liu	Deputy General Manager	8.9yrs	CN¥908.50k	0.014% CN¥ 2.2m
Lijian Zhao	GM & Director	no data	sin datos	0.023% CN¥ 3.6m
Yujue Wang	Chief Financial Officer	no data	sin datos	sin datos
Hui Liu	Head of the accounting department & Accounting Supervisor	no data	sin datos	sin datos
Huo Shoujiang	Director of Human Resources	no data	sin datos	sin datos
Ning Li	Deputy GM & Director	less than a year	sin datos	0.032% CN¥ 5.1m
Weijun Chen	Deputy General Manager	no data	sin datos	sin datos
Zhu Shida	Deputy General Manager	no data	sin datos	sin datos

8.9yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300676 es experimentado (8.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ye Yin	Vice Chairman of the Board	8.9yrs	CN¥2.62m	0.28% CN¥ 44.5m
Yutao Du	COO, Deputy GM & Director	5.5yrs	CN¥453.10k	0.025% CN¥ 3.9m
Lijian Zhao	GM & Director	2.9yrs	sin datos	0.023% CN¥ 3.6m
Ning Li	Deputy GM & Director	less than a year	sin datos	0.032% CN¥ 5.1m
Leroy Hood	Member of Scientific Advisory Board	7.2yrs	sin datos	sin datos
Jian Wang	Chairman	8.9yrs	sin datos	0.67% CN¥ 106.1m
Yu Jie Hu	Member of Supervisory Board	8.9yrs	sin datos	0.00092% CN¥ 145.9k
Hongtao Wang	Director	8.2yrs	sin datos	sin datos
Ya Cao	Independent Director	2.9yrs	sin datos	sin datos
Lan Du	Independent Director	2.9yrs	sin datos	sin datos
Siqi Liu	Chairman of the Supervisory Board	2.9yrs	sin datos	sin datos
Lisheng Yu	Independent Director	less than a year	sin datos	sin datos

4.2yrs

Permanencia media

48yo

Promedio de edad

Junta con experiencia: La junta directiva de 300676 se considera experimentada (4.1 años de antigüedad promedio).

BGI Genomics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.091 in 1Q 2023)

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024

BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022)

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022)

BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023

First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022)

Investor sentiment improves as stock rises 30%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021)

BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022

BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020)

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Investor sentiment improved over the past week

BGI Genomics Co., Ltd. (SZSE:300676) completed the acquisition of remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd.

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

BGI Genomics Co., Ltd. Approves Cash Dividend for 2020

BGI Genomics Co., Ltd. (SZSE:300676) agreed to acquire the remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. for CNY 2.37 million.

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2020

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020)

New 90-day low: CN¥125

Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019)

Revenue and earnings miss expectations

Investor sentiment deteriorated over the past week

New 90-day high: CN¥166

Investor sentiment improved over the past week

New 90-day low: CN¥127

New 90-day low: CN¥133

Third quarter earnings released

New 90-day low: CN¥133

First half earnings released

BGI Genomics Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

BGI Genomics Co., Ltd. announced that it expects to receive CNY 2.0119372 billion in funding

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad